Boehringer Ingelheim expands cancer research at its Vienna site
25 sept. 2024 10h45 HE
|
Boehringer Ingelheim
Inauguration of Angelika Amon research building in Vienna Sustainable research building at a cost of EUR 60 million offers modern office and laboratory spaceOver the past five years, Boehringer’s...
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
25 sept. 2024 08h30 HE
|
PRISM MarketView
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
25 sept. 2024 08h30 HE
|
RenovoRx, Inc.
LOS ALTOS, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies based on a...
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
24 sept. 2024 11h09 HE
|
Tevogen Bio Inc
WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Custom Antibody Services Market to Reach $1.4 Billion, Globally, by 2033 at 8.7% CAGR: Allied Market Research
24 sept. 2024 09h36 HE
|
Allied Analytics LLP
Wilmington, Delaware, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Custom Antibody Services Market by Service (Antibody Development, Antibody Production and...
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
24 sept. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
Nuclear Medicine Market Projected Growth at 9.2% CAGR to Reach USD 11.4 billion by 2031 | Exclusive Research Report by Transparency Market Research Inc.
23 sept. 2024 06h58 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 23, 2024 (GLOBE NEWSWIRE) -- According to a report published by Transparency Market Research, the global nuclear...
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
20 sept. 2024 09h00 HE
|
FN Media Group LLC
PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer...
Keck Graduate Institute Awarded $750,000 Grant from the Department of Energy to Study Low-Level Radiation Effects
19 sept. 2024 14h34 HE
|
Keck Graduate Institute
Claremont, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Keck Graduate Institute (KGI), a member of The Claremont Colleges, has been awarded a significant grant from the Department of Energy to investigate...
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
19 sept. 2024 08h00 HE
|
AIM ImmunoTech Inc.
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no...